Katherine A. Eade - 16 Jul 2025 Form 4 Insider Report for HARVARD BIOSCIENCE INC (HBIO)

Reporting relationship: Director
Issuer ticker: HBIO
Reported as of: 16 Jul 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 18 Jul 2025, 16:33:54 UTC
Prior SEC filing: 23 May 2024
Next SEC filing: 12 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Katherine Eade

Key filing fact

Katherine A. Eade filed Form 4 for HARVARD BIOSCIENCE INC (HBIO) on 18 Jul 2025.

Key facts

This page summarizes Katherine A. Eade's Form 4 filing for HARVARD BIOSCIENCE INC (HBIO).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 18 Jul 2025, 16:33.

Change

Previous filing in this sequence was filed on 23 May 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001721318 Primary reporting owner

Eade Katherine A.

Relationship: Director
Address: C/O HARVARD BIOSCIENCE, INC., 84 OCTOBER HILL ROAD, HOLLISTON
Signature: /s/ Katherine Eade
Signature date: 18 Jul 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

HBIO transaction

Common Stock

Award

Transaction value: $0
Shares: +110,000
Change %: +35%
Price: $0.000000
Shares after: 421,126
Date: 16 Jul 2025
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents an award of 110,000 restricted stock units that fully vest on the earlier to occur of (i) the date of the Issuer's next Annual Meeting of Stockholders after July 16, 2025, immediately prior to the commencement of such meeting, and (ii) July 16, 2026.

Footnote F2

Includes (a) the award described in footnote (1) above and (b) 311,126 shares of common stock beneficially owned by the Reporting Person.